BIO vs DGX: fair value comparison
Bio-Rad Laboratories, Inc. and Quest Diagnostics Incorporated · Updated 2026-09-13
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, DGX currently sits closer to the top of our discount ranking. BIO carries the stronger quality grade.
| BIO | DGX | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $380.96 | $235.02 |
| 12-month range | $256.55–$380.96 | $171.57–$236.22 |
| Sector rank | #105 of 113 Healthcare | #103 of 113 Healthcare |
| Quality grade | A | B |
| Leverage | Low | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BIO fair value analysis · DGX fair value analysis